Reimbursed Care Access in Malta

Currently classified as a strictly controlled substance under international psychotropic scheduling and Maltese/European implementation, with no authorised medical use outside of approved clinical research. Psilocybin (and its active metabolite psilocin) appear on the international schedules that inform national law and are treated in Malta as controlled psychotropic substances; access is therefore limited to authorised clinical trials or tightly regulated research protocols. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any use outside approved trials would be unlawful; criminal penalties and enforcement apply under Malta’s implementation of international drug control treaties. #

Esketamine nasal spray (Spravato) received a centralized EU marketing authorisation (CHMP/EMA opinion and EC authorisation), meaning it is authorised for use in EU member states including Malta under the EU marketing framework; the EMA decision and EPAR record describe the indication as adults with treatment‑resistant major depressive disorder in combination with an oral SSRI/SNRI (with specific monitoring and supervised administration requirements). #

Practical access and reimbursement in Malta: because Spravato is an EU‑authorised medicinal product, it may be placed on the Maltese market by the MAH and made available to clinicians who are certified to administer it. However, EU authorisation does not automatically guarantee public‑sector reimbursement or routine availability within the Maltese public health service; implementation (whether the product is stocked, which hospital/clinic services provide it, and whether National Health Service/Health Insurance covers it) is determined at national level and may require local formulary decisions, provider certification under the product's risk‑management program, and budgetary approval. In practice, manufacturers and regulators require supervised administration (certified settings, patient observation) and local health services or private clinics must implement those requirements before offering treatment. For Malta specifically, policy and service‑level uptake has been limited and public‑sector availability appears constrained; patients or clinicians often need to pursue private provision or case‑by‑case arrangements. # #

Reimbursement note: there is no single pan‑Malta published public reimbursement listing that uniformly guarantees Spravato reimbursement for all eligible patients; where Spravato is used in Malta it will generally be under the EMA label with institution‑level decisions about funding (private clinic fees or hospital budget lines). Clinicians seeking esketamine for patients in Malta should consult the Maltese Ministry of Health / national formulary and the product marketing authorisation holder for the current local access and funding position. #

Ketamine is an established anaesthetic and analgesic used in hospitals; the molecule itself is available and used in Maltese health services for licensed indications (anaesthesia, analgesia) but its use as an antidepressant (repeated low‑dose IV or IM protocols for treatment‑resistant depression) is generally off‑label and not a routinely reimbursed, standard public‑sector service in Malta. The World Health Organization recognises ketamine as an essential medicine for certain clinical uses, supporting hospital availability for anaesthesia/analgesia. #

Local regulatory/health‑service stance (Malta): Maltese mental‑health authorities have previously advised caution and indicated that evidence, posology and safety data for ketamine infusions in TRD were insufficient for routine introduction into the public system; institutional approval is therefore required and, historically, introduction of ketamine infusion services for TRD in Malta has been discouraged absent stronger regulatory authorisation and service frameworks. That means ketamine for depression is principally accessed off‑label via private clinics or cross‑border care rather than as a standard reimbursed public treatment. (Example: correspondence from Maltese mental‑health officials referencing lack of authorisation/insufficient evidence for routine ketamine infusion services). #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is listed among internationally controlled psychotropic substances and is treated as a controlled drug in Malta; access is limited to authorised research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as a controlled tryptamine analogue in most jurisdictions applying the 1971 Convention principles, and Malta implements strict controls accordingly. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine’s legal status varies internationally but in Malta it is not an authorised medical treatment and any clinical use would be restricted to approved research or exceptional regulatory pathways. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT (a controlled psychotropic), their possession, preparation and distribution are prohibited except under authorised scientific or medical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled under the international psychotropic schedules that inform Maltese law; possession or sale outside authorised research is unlawful. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family (arylalkylamine psychedelics/phenethylamine analogues commonly referred to as “2C‑X”) are controlled in most jurisdictions and are not available medically in Malta except within authorised research. #